Jinhua Zhang

TL;DR: Although monotherapy and combination therapy with mTOR inhibitors have been extensively applied in preclinical and clinical trials in various cancer types, innovative therapies with better efficacy and less drug resistance are still in great need, and new biomarkers and deep sequencing technologies will facilitate these mTOR targeting drugs benefit the cancer patients in personalized therapy.

TL;DR: Though substantial progress has been made in understanding the role of oxidative stress in IBD in humans and experimental animals, the underlying mechanisms are still not well defined and further studies are needed to validate how oxidative stress signaling is involved in and contributes to the development of IBD.

TL;DR: A novel m6A reader, Prrc2a (Proline rich coiled-coil 2 A), is identified, which controls oligodendrocyte specification and myelination and suggests a new avenue for the development of therapeutic strategies for hypomyelination-related neurological diseases.

TL;DR: S100A4 promotes liver fibrosis by activating HSCs, which may represent a potential target for anti-fibrotic therapies and examined its mechanism by focusing on the activation of hepatic stellate cells (HSCs).

TL;DR: The results show that IFNgamma, under certain conditions, may promote tumor development by enhancing a Th17-associated inflammatory reaction in draining lymph nodes after DMBA/TPA treatment.